Background: Patients with sepsis syndrome commonly have low serum selenium levels. Several randomized controlled trials have examined the efficacy of selenium supplementation on mortality in patients with sepsis. Objective: To determine the efficacy and safety of high-dose selenium supplementation compared to placebo for the reduction of mortality in patients with sepsis. Sources of Data: We searched Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, SciFinder, and Clinicaltrials.gov. Selection Criteria: Randomized controlled parallel group trials comparing selenium supplementation in doses greater than daily requirement to placebo on the outcome of mortality in patients with sepsis syndrome. Data Collection and Analysis: Two reviewers independently applied eligibility criteria, assessed quality, and extracted data. The primary outcome was mortality; secondary outcomes were ICU length of stay, nosocomial pneumonia, and adverse events. Trial authors were contacted for additional or clarifying information. Results: Nine trials enrolling a total of 792 patients were included. Selenium supplementation in comparison to placebo was associated with lower mortality (odds ratio, 0.73; 95% CI, 0.54, 0.98; p = 0.03; I 2 = 0%). Among patients receiving and not receiving selenium, there was no difference in ICU length of stay (mean difference, 2.03; 95% CI, -0.51, 4.56; p = 0.12; I 2 = 0%) or nosocomial pneumonia (odds ratio, 0.83; 95% CI, 0.28, 2.49; p = 0.74; I 2 = 56%). Significant heterogeneity among trials in adverse event reporting precluded pooling of results. Conclusions: In patients with sepsis, selenium supplementation at doses higher than daily requirement may reduce mortality. We observed no impact of selenium on ICU length of stay or risk of nosocomial pneumonia. (Crit Care Med 2013; 41:1555-1564 
high initial bolus doses of selenium compounds (e.g., sodium selenite) may have pro-oxidant effects that could be beneficial in sepsis through reversible inhibition of NF-ĸB binding to DNA, cytokine production blockade, or apoptosis induction of proinflammatory cells (6) . This pro-oxidant effect is suggested to be transient, as selenium is rapidly incorporated into antioxidant selenoenzymes. Oxidative stress and free oxygen species might contribute to the development of multiple organ failure in septic shock (7) , and the need for selenium as a key component of the endogenous antioxidant defense might be increased in shock. This concept is further supported by facts that seleniumdependent glutathione peroxidase activity is regulated mainly by the availability of selenium (8) (9) (10) (11) and that the activity of the selenium-dependent glutathione peroxidases in serum correlated inversely with the severity of the sepsis (12, 13) .
The recommended dietary daily requirement for healthy adult patients ranges between 60 and 100 mcg/day (1) . However, the ideal dose, duration, and route of selenium supplementation in ICU patients have not been established. Selenium supplementation exists in both enteral and parenteral forms; sodium selenite is the only parenteral form (14) . Selenium toxicity (selenosis) is well described in the literature and is characterized by nausea, vomiting, loss of hair and nails, skin rash, tooth decay, skin lesions, fatigue, and peripheral neuropathy (15) . The maximum safe daily dose for selenium is not clear, but a dose of 5 mcg/kg/day does not appear to be associated with adverse events, and up to 1,000 mcg/day of selenite can be used for short-term supplementation (14, 16) . In the study by Manzanares et al (17) , the investigators used an initial loading dose of 2,000 mcg sodium selenite over the first 2 hours, and Forceville et al (18) used 4,000 mcg as an infusion over the first 24 hours.
Current evidence suggests that in critically ill patients, low selenium levels are associated with higher risk of death, multiple organ failure, and higher markers of oxidative stress (19) . In a prospective cohort study enrolling critically ill patients, those with systematic inflammatory response syndrome (SIRS) and severe sepsis were found to have 40% lower selenium levels than patients without SIRS (12) . Low selenium concentrations have been demonstrated in patients with sepsis syndromes and variably associated with poor outcomes (morbidity and mortality) (12, (20) (21) (22) . Although selenium is an acute phase reactant and interpreting levels in the ICU is challenging, these observations have led to increased recent interest in the value of selenium supplementation in critically ill patients (23) . There are reports of benefits of selenium in other noninfectious insults, namely, cardiac arrest (24) and postoperative multiple organ failure (25) . Whether the benefits of selenium treatment share a common pathway in these conditions remains to be elucidated.
Several randomized controlled trials (RCTs) of selenium have enrolled patients with sepsis syndrome (17, 18, 21, 22, (26) (27) (28) (29) (30) (31) , but no prior meta-analysis has examined the effect of selenium on survival in this population. The objective of this systematic review was to examine the effect of selenium supplementation on mortality in the context of the sepsis syndrome.
METHODS

Eligibility Criteria
We included trials with the following characteristics: 
Data Extraction
Using a standardized data extraction sheet, two reviewers (W.A., A.S.) independently extracted data with disagreements resolved by discussion and consensus. Authors of included trials were contacted for missing or unclear information.
Methodologic Quality Assessment
The methodologic quality of the included trials was assessed using the Cochrane risk of bias tool recommended by the Cochrane collaboration (32) . For each included trial, a description, a comment, and a judgment as "high," "unclear," or "low" risk of bias was provided for each of the following items: adequate random sequence generation; allocation sequence concealment; blinding for objective outcomes; incomplete outcome data; free of selective outcome reporting; and free of other bias. The overall risk of bias for an individual trial was categorized as "low" (if the risk of bias is low in all domains), "unclear" (if the risk of bias is unclear in at least one domain, with no high risk of bias domains), or "high" (if the risk of bias is high in at least one domain).
Two reviewers (W.A., A.S.) assessed the methodologic quality of trials independently; disagreements were resolved by discussion and consensus. The overall quality of evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach that considers: 1) risk of bias in individual trials, 2) consistency of results across trials, 3) potential for publication bias, 4) precision of pooled estimates, and 5) suitability of the individual study populations, interventions, and outcome assessments in directly addressing the question of this review (33) .
Statistical Analysis
We analyzed data using RevMan 5.1 with a random effects model. We calculated pooled odds ratio (OR) for dichotomous outcomes and mean differences for continuous outcomes; each with associated 95% CIs. Statistical heterogeneity was assessed by the Mantel-Haenzel chi-square test and the I² statistic. Substantial heterogeneity was predefined as p < 0.10 with the Mantel-Haenzel chi-square test or an I² > 50%. Number needed to treat (NNT) was calculated based on an assumed control risk of 40% for mortality outcome. The Egger test was used to measure funnel plot asymmetry (34) .
Exploring Heterogeneity
Despite the absence of statistical heterogeneity, we conducted three planned subgroup analyses to test the robustness of the results. A priori we defined one subgroup analysis according to selenium dose (i.e., 500 mcg or less per day vs more than 500 mcg per day), hypothesizing that high-dose selenium will have a larger treatment effect. A second group analysis was conducted according to methodologic quality (i.e., low vs high or unclear risk of bias), hypothesizing that trials with a high risk of bias would have a larger treatment effect. The third subgroup analysis was according to severity of sepsis (i.e., septic shock vs other sepsis syndromes), hypothesizing that patients with septic shock will have a larger treatment effect.
We conducted one sensitivity analysis, defined a priori, which examined the effect of different measures of treatment effect on the results (i.e., comparing OR, risk difference, and relative risk [RR] ).
RESULTS
Study Location and Selection
We identified a total of 254 titles and abstracts after the primary search; 205 articles remained after de-duplicating citations. After screening the titles and abstracts, 184 were nonrelevant and were excluded. The remaining 21 articles were retrieved for eligibility assessment; of those, 12 were excluded (Supplemental Digital Content 1, http://links.lww.com/CCM/A686). A total of nine trials fulfilled eligibility criteria and were included in this meta-analysis ( Fig. 1) .
Assessment of Methodologic Quality
Using the Cochrane risk of bias tool, only two trials were judged to be at low risk of bias (high methodological quality), three trials were at high risk of bias (low methodological quality), and four trials with unclear risk of bias. Only four trials reported appropriate allocation concealment, and four trials described appropriate blinding. The details are shown in Figure 2 . The GRADE method (33) was used to assess the quality of evidence among trials for each individual outcome. The overall findings are presented in the summary of findings table ( Table 1) .
Publication Bias
We detected no evidence of publication bias by assessing funnel plot either visually (Fig. 3) or statistically (Egger test = -0.73; 95% CI, -2.60, 1.15; p = 0.38).
Summary of Studies
We included nine trials that compared intravenous sodium selenite supplementation to placebo in ICU patients with sepsis syndromes. Sepsis syndromes included the following: SIRS (17, 21, 22, 27, 29, 31) , sepsis (21, 22, 26) , and septic shock (18, 21, 28) . The authors of two trials kindly provided us with data on the subgroup of patients with sepsis, which we included in the primary analysis (17, 26) . High-dose selenium (more than 500 mcg per day) was used in five trials and the other four used selenium at doses less than 500 mcg per day. The included trials are summarized in Table 2 .
Mortality
Nine trials including 792 patients reported mortality as an outcome (Fig. 4) . We pooled mortality at the longest period of follow-up from each trial. Overall, there was a statistically significant reduction in mortality (OR, 0.73; 95% CI, 0.54, 0.98; p = 0.03; I 2 = 0%). The NNT to prevent one death was 13 for an assumed controlled risk of 40%. 
ICU Length of Stay
Three trials enrolling 251 patients reported mean ICU length of stay with SD. There was no difference in ICU length of stay between groups (mean difference, 2.03; 95% CI, -0.51, 4.56; p = 0.12; I 2 = 0%).
Nosocomial Pneumonia
Three trials enrolling 271 patients reported nosocomial pneumonia rates (Fig. 5) . There was no difference between groups in the risk of developing nosocomial pneumonia with selenium supplementation (OR, 0.83; 95% CI, 0.28, 2.49; p =0.74; I 2 = 56%).
Adverse Events
Due to variation in reporting the type and completeness of adverse events among trials, we did not conduct a meta-analysis for this outcome.
Subgroup Analysis
There was no difference in the treatment effect on mortality between subgroups of trials using higher versus lower doses of selenium (Fig. 6) . There was no difference in the treatment effect between subgroups of higher versus lower quality trials (Fig. 7) . Due to lack of specificity in the original trial reports, we were not able to conduct the third planned subgroup analysis according to severity of sepsis (septic shock vs other sepsis syndrome).
Sensitivity Analysis
We conducted one set of sensitivity analyses, examining the effect of using RR as a measure of treatment effect (RR, 0.84; 95% CI, 0.71, 1.00; p = 0.05; I 2 = 0%) and using risk difference as a measure of treatment effect (risk difference, -0.08; 95% CI, -0.14, -0.01; p = 0.02; I 2 = 0%). These observations suggest that the overall direction of treatment effect is in favor of selenium, but its statistical interpretation is sensitive to the measure of effect used, in that OR and risk difference yielded a significantly lower risk of death than when the measure of effect was RR.
DISCUSSION
Sepsis is associated with an increase in reactive oxygen species, low endogenous antioxidative capacity, and reduced selenium levels. Because selenoenzymes are important for antioxidant defense, adjuvant supplementation with selenium may improve the outcome of patients with sepsis. However, clinical trials of selenium supplementation to date have shown inconsistent results. In this meta-analysis of randomized trial enrolling patients with sepsis, we found that selenium supplementation with a higher than daily recommended dose (more than 100 mcg per day) may reduce mortality. We did not observe an effect on the duration of ICU length of stay or the rate of nosocomial pneumonia. The dose-effect relationship of selenium is unclear. Adjusted hazard ratios for all-cause mortality according to serum selenium concentration in the adult population describes a U curve, indicating negative outcomes for both very low and very high serum levels (35) . Trials with selenium supplementation in patients with sepsis were conducted using different dosing schedules. Most trials used selenium intravenously in doses up to 1,000 mcg except for Forceville et al (18) who administered a high-dose continuous infusion in an attempt to achieve a pro-oxidant effect in 60 patients with septic shock. Patients received 4,000 mcg of continuously infused selenium on the first day followed by 1,000 mcg/day as a continuous infusion for the subsequent 9 days. The cumulative dose of sodium selenite was 13 mg per patient. This trial revealed no effect on time to vasopressor withdrawal, duration of mechanical ventilation, ICU or hospital lengths of stay, or mortality rates. Angstwurm et al (29) treated 249 patients with severe SIRS, sepsis, or septic shock with either 1,000 mcg of sodium selenite as a 30-minute bolus, followed by 14 daily continuous intravenous infusions of 1,000 mcg, or placebo. The cumulative selenium dose was approximately 15 mg per patient over 14 days. There were some protocol violations, and 28-day mortality rates were only significantly lower in the per-protocol analysis (n = 189 patients, p = 0.049), but not in the intention-to-treat analysis (n = 238 patients, p = 0.10). Both of the foregoing trial studies had used similar cumulative selenium doses. The lack of reported effect in the study by Forceville et al could have been due to the lower sample size or the fact that selenium was not administered as bolus.
Our subgroup analysis suggested that selenium supplementation in doses above 500 mcg was associated with lower mortality (OR, 0.62; 95% CI, 0.43, 0.89). This supports conclusions from other investigators, which suggested that high-dose selenium protocols appear to be safe for optimization of plasma levels and extracellular glutathione peroxidase antioxidant activity (13, 23) .
Our results need to be interpreted in relation to three prior meta-analyses. One meta-analysis of seven RCTs enrolled 186 heterogeneous critically ill patients (not confined to sepsis populations), which tested selenium therapy (some trials tested other antioxidants concurrently (19) ). This meta-analysis showed a trend toward lower mortality with selenium (RR, 0.59; 95% CI, 0.32, 1.08; p = 0.09), although the use of nonselenium antioxidants (vitamins A, C, E, and zinc) appeared (36) , which included 476 critically ill patients enrolled in seven RCTs, showed no impact of selenium therapy on mortality (RR, 0.75; 95% CI, 0.53, 1.06). Similar to our findings that selenium had no impact on infectious complications (e.g., nosocomial pneumonia) in septic patients, Avenell et al (36) did not identify an effect on such complications in heterogeneous ICU patients (RR, 1.2; 95% CI, 0.67, 2.23; I 2 = 0%). Third, a recently published meta-analysis reexamined diverse critically ill populations (not confined to septic patients) and diverse antioxidants (including selenium), including 21 RCTs that included over 2,400 patients. This review found a significant reduction in mortality (risk ratio, 0.82; 95% CI, 0.72, 0.93), a significant reduction in duration of mechanical ventilation (weighed mean difference in days = -0.67; 95% CI, -1.22, -0.13), and a trend toward a reduction in infections (RR = 0.88; 95% CI, 0.76, 1.02 [30] ). Our meta-analysis targeted a specific ICU population with sepsis syndrome and isolated the effect of a specific trace element (selenium), in contrast to prior systematic reviews enrolling broader groups of patients exposed to supplement combinations. In terms of safety, there was variable reporting of adverse events across trials in our review. However, examining individual trials, selenium even at high doses was not associated with significant side effects, consistent with the results of Avenell et al (36) , which yielded a pooled RR for adverse events of 0.75, 95% CI: 0.40, 1.43, I 2 = 57%. Surprisingly, there is a paucity of experimental studies on selenium therapy in sepsis. Conducting formal experimental studies in sepsis models could shed more light on the mechanisms of action and help to optimize the dosing regimen and duration of therapy, even though the currently reported prevalence of adverse effects from clinical studies is low.
The strengths of this systematic review include comprehensive search strategy that included non-English articles, use of GRADE methodology, and duplicate assessment of both risk of bias and data abstraction. We focused on a unique ICU population with sepsis syndrome and examined the isolated efficacy of a specific trace element (selenium). Additional data obtained in collaboration with some trial authors helped to refine our analyses. The inferences from these results are limited by a number of factors. First, most of the included trials were of low or unclear methodologic quality (Fig. 2) . The potential importance of this issue is highlighted by the fact that subgroup analysis comparing mortality estimates among trials with higher methodologic quality versus other trials suggested that the potential benefit is not clearly apparent among higher quality trials, although this subgroup difference was not statistically significant (Fig. 7) . Second, different measures of treatment effect in the sensitivity analysis led to somewhat different quantitative results; focusing only on p values, the results were just significant (p = 0.05) when using RR as a measure of treatment effect, whereas they were significant when OR and risk difference were the metrics used as a summary measure (p < 0.05). Consequently, using the GRADE approach, we judged the overall quality of evidence for the mortality benefit to be low due to imprecision of the results as well as methodologic limitations.
The cost of selenium is relatively low, although it varies widely across locations, even within countries, due in part to bulk purchasing agreements. According to the British National Formulary, a 2-mL ampoule of 50 mcg/mL costs £1.50 (37) . The cost of 1,000 mcg of sodium selenite is approximately 14 euros in Germany (K Reinhart, personal communication, 2012). Therefore, if even a small favorable impact of selenium was genuine, given the low risk of adverse effects, and the high human and financial cost of critical care, selenium supplementation deserves consideration in more rigorous future research.
In conclusion, selenium appears to have a promising impact on patients with sepsis syndromes. However, we believe that further large rigorous trials are needed to confirm or refute these findings before practice implications are clear. The Canadian Critical Care Trials Group has recently completed a factorial RCT that enrolled 1,200 patients with organ failure (many of whom had sepsis), who were randomized to either placebo or a combination of selenium, zinc, beta carotene, vitamin E, and vitamin C, and who were also randomized to either placebo or parenteral glutamine (ClinicalTrials. gov, NCT00133978) to examine mortality. The SepNet Clinical Trials Group is currently conducting a trial focused on severe sepsis or septic shock, which has enrolled over 800 patients to evaluate the effect of sodium selenite on mortality (ClinicalTrials.gov, NCT00832039). We await the results of these trials with interest.
